Clinical significance of relative dose intensity during pazopanib treatment to advanced/metastatic soft tissue sarcoma (STS) patients.
Kenji Nakano(National Center for Global Health and Medicine), Shunji Takahashi(Japanese Foundation For Cancer Research), Keiko Hayakawa(Cancer Institute (WIA)), Seiichi Matsumoto(Fukuda Denshi (Japan)), Taisuke Tanizawa(Japanese Foundation For Cancer Research), Tabu Gokita, Yoshiya Sugiura(Japanese Foundation For Cancer Research), Keisuke Ae(The Cancer Institute Hospital), Yuki Funauchi(Japan Association for Development of Community Medicine), Shinichiro Taira(Japanese Foundation For Cancer Research), Junichi Tomomatsu(The Cancer Institute Hospital)
Cited by 0
Related Papers
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264
Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases
|International Journal of Radiation Oncology*Biology*Physics|2016|182